We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Myoglobin Gene Mutation Causes New Muscle Disease

By LabMedica International staff writers
Posted on 08 Apr 2019
Image: Photomicrographs of tissues from patients with myoglobinopathy, a new muscular disease caused by a mutation in the myoglobin gene (Photo courtesy of Bellvitge Biomedical Research Institute).
Image: Photomicrographs of tissues from patients with myoglobinopathy, a new muscular disease caused by a mutation in the myoglobin gene (Photo courtesy of Bellvitge Biomedical Research Institute).
The cause of myoglobinopathy, a newly described disease of the muscles, has been traced to a mutation in the gene that encodes for the protein myoglobin (MB).

Myoglobin, like hemoglobin (Hb), is a cytoplasmic protein that binds oxygen on a heme group. It harbors only one heme group, whereas hemoglobin has four. Although its heme group is identical to those in Hb, MB has a higher affinity for oxygen than does hemoglobin. This difference is related to its different role: whereas hemoglobin transports oxygen, myoglobin's function is to store oxygen. MB also acts as scavenger of free radicals and other reactive oxygen species, helping the cell to avoid damage caused by oxidative stress.

The newly characterized disease called myoglobinopathy manifests between the fourth and fifth decade of life. It causes a progressive weakness of the axial and limb muscles, and in more advanced stages affects the respiratory musculature and the heart.

Investigators at the Bellvitge Biomedical Research Institute (Barcelona, Spain) analyzed the genomes of fourteen members of six unrelated European families who displayed signs of myoglobinopathy. They identified an autosomal dominant myopathy with variable cardiac involvement and characteristic sarcoplasmic inclusions in skeletal and cardiac muscle that was linked to a recurrent substitution mutation in the MB gene.

Biochemical characterization revealed that the mutant myoglobin had altered oxygen binding, exhibited a faster heme dissociation rate, and had a lower reduction potential compared to wild-type myoglobin. Preliminary studies showed that effects of the myoglobin mutation caused elevated superoxide levels at the cellular level.

"This is the first time that a disease caused by a mutation in the myoglobin gene has been identified," said first author Dr. Montse Olivé, a physician and researcher in the institute of neuropathology at the Bellvitge Biomedical Research Institute. "We have identified the same mutation in several members of six unrelated European families, all of whom had the same symptoms and showed very characteristic lesions - called sarcoplasmic bodies - in muscle biopsies."

The genetic basis of myoglobinopathy was discussed in a paper published in the March 27, 2019, online edition of the journal Nature Communications.

Related Links:
Bellvitge Biomedical Research Institute

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Hemodynamic System Monitor
OptoMonitor
Blood Glucose Test Strip
AutoSense Test

Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more